Successful Tigecycline Use in Combined Therapy of Ventilator-Associated Hospital-Acquired Pneumonia: a Clinical Case

In patients under artificial lung ventilation (ALV) there is often observed development of severe ventilator-associated pneumonia (VAP) due to polyresistant hospital pathogens. It should be noted that in the patient described here with the initial diagnosis of community-acquired pneumonia rapidly subjected to prolonged ALV the previous antibacterial therapy by broad spectrum drugs significantly increased the risk of contamination just by multiresistant nosocomial strains, which hampered the starting therapy of nosocomial pneumonia either when there were not available or sometimes there were available microbial cultures. When the treatment of severe pneumonias caused by multiresistant hospital flora resistant to carbapenems is actual, in the alternative therapy it could be used tigecycline, a tetracycline from the group of glycylcyclines. A case of successful treatment of nosocomial VAP by tigecycline based on the results of the bronchoalveolar lavage (BAL) culture is described. The case is of interest because tigecycline was used as off label.

multidrug-resistant A.baumannii (MDRAB), community-acquired pneumonia, nosocomial pneumonia, tetracycline, tigecycline, Tigacyl, multidrug-resistant A.baumannii (MDRAB)

1. Гельфанд Б.Р., Белоцерковский Б.З., Милюкова И.А., Гельфанд Е.Б. Эпидемиология и нозологическая структура нозокомиальных инфекций в отделении реанимации и интенсивной терапии многопрофильного стационара. Инфекции в хирургии. 2014; 4: 24-36. / Gelfand B.R., Belocerkovskij B.Z., Miljukova I.A., Gelfand E.B. Jepidemiologija i nozologicheskaja struktura nozokomial'nyh infekcij v otdelenii reanimacii i intensivnoj terapii mnogoprofil'nogo stacionara. Infekcii v hirurgii. 2014; 4: 24-36. [in Russian]

2. Sunenshine R.H., Wright M.O., Maragakis L.L., Harris A.D., Song X., Hebden J. et al. Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis 2007; 13: 97-103.

3. Wareham D.W., Bean D.C., Khanna P., Hennessy E.M., Krahe D., Ely A. et al. Bloodstream infection due to Acinetobacter spp. epidemiology, risk factors and impact of multidrug resistance. Eur J Clin Microbiol Infect Dis 2008; 27: 607-612.

4. Fagon J.Y., Chastre J., Hance A.J., Montravers P., Novara A., Gibert C. Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. Am J Med 1993; 94: 281-288.

5. Falagas M.E., Bliziotis I.A., Siempos I.I. Attributable mortality of Acinetobacter baumannii infections in critically ill patients: a systematic review of matched cohort and case-control studies. Crit Care 2006; 10: R484.

6. Fagon J.Y., Chastre J., Hance A.J., Montravers P., Novara A., Gibert C. Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. Am J Med 1993; 94: 281-288.

7. Falagas M.E., Koletsi P.K., Bliziotis I.A. The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J Med Microbiol 2006; 55: Pt 12: 1619-162916.

8. Falagas M.E., Rafailidis P.I. Attributable mortality of Acinetobacter baumannii: no longer a controversial issue. Crit Care 2007; 11: 134.

9. Cisneros J.M., Reyes M.J., Pachon J., Becerril B., Caballero F.J., GarcfaGarmendfa J.L. et al. Bacteremia due to Acinetobacter baumannii: epidemiology, clinical findings, and prognostic features. Clin Infect Dis 1996; 22: 1026-1032.

10. Gordon N.C., Wareham D.W. A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline. J Antimicrob Chemother 2009; 63: 775-780.

11. Lee K., Yong D., Jeong S.H., Chong Y. Multidrug-resistant Acinetobacter spp.: increasingly problematic nosocomial pathogens. Yonsei Med J. 2011; 52: 879-891.

12. Chin B.S., Han S.H., Choi S.H., Lee H.S, Jeong SJ, Choi H.K et al. The characteristics of metallo-/?-lactamase-producing gram-negative bacilli isolated from sputum and urine: a single center experience in Korea. Yonsei Med J 2011; 52: 351-357.

13. Dalla-Costa L.M., Coelho J.M., Souza H.A., Castro M.E, Stier C.J., Bragagnolo K.L. et al. Outbreak of carbapenem-resistant Acinetobacter baumannii producing the OXA-23 enzyme in Curitiba, Brazil. J Clin Microbiol 2003; 41: 3403-3406.

14. Lee K., Kim M.N., Kim J.S., Hong H.L., Kang J.O., Shin J.H. et al. Further increases in carbapenem-, amikacin-, and fluoroquinolone-resistant isolates of Acinetobacter spp. and P.aeruginosa in Korea: KONSAR study 2009.Yonsei Med J 2011; 52: 793-802.

15. Manuel R.J., Shin G.Y., Farrag N., Holliman R. Endemic carbapenemresistant Acinetobacter baumannii in a London hospital. J Antimicrob Chemother 2003; 52: 141-142.

16. Coelho J.M., Turton J.F., Kaufmann M.E., Glover J., Woodford N., Warner M. et al. Occurrence of carbapenem-resistant Acinetobacter baumannii clones at multiple hospitals in London and Southeast England. J Clin Microbiol 2006; 44: 3623-3627.

17. Turner P.J. MYSTIC Europe 2007: activity of meropenem and other broad-spectrum agents against nosocomial isolates. Diagn Microbiol Infect Dis. 2009; 63: 217-222.

18. Rhomberg P.R., Jones R.N.Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999-2008) Diagn Microbiol Infect Dis. 2009; 65: 414-426.

19. Dizbay M., Altuncekic A., Sezer B.E., Ozdemir K., Arman D. Colistin and tigecycline susceptibility among multidrug-resistant Acinetobacter baumannii isolated from ventilator-associated pneumonia. Int J Antimicrob Agents 2008; 32: 29-32.

20. Falagas M.E., Kasiakou S.K., Rafailidis P.I., Zouglakis G., Morfou P. Comparison of mortality of patients with Acinetobacter baumannii bacteraemia receiving appropriate and inappropriate empirical therapy. J Antimicrob Chemother 2006; 57: 1251-1254.

21. Garnacho-Montero J., Garcia-Garmendia J.L., Barrero-Almodovar A., Jimenez-Jimenez F.J., Perez-Paredes C., Ortiz-Leyba C. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 2003; 31: 2742-2751.

22. Oh J.Y., Kim K.S., Jeong Y.W., Cho J.W., Park J.C., Lee J.C. Epidemiological typing and prevalence of integrons in multiresistant Acinetobacter strains. APMIS 2002; 110: 247-252.

23. Humphreys H., Towner K.J. Impact of Acinetobacter spp. in intensive care units in Great Britain and Ireland. J Hosp Infect. 1997; 37: 281-286.